Cogent Biosciences, Inc. (COGT)

NASDAQ: COGT · IEX Real-Time Price · USD

7.77 -0.36 (-4.43%)

Jan 18, 2022 4:00 PM EST - Market closed

Market Cap	309.64M
Revenue (ttm)	n/a
Net Income (ttm)	-163.10M
Shares Out	39.85M
EPS (ttm)	-4.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	233,507
Open	8.12
Previous Close	8.13
Day's Range	7.56 - 8.28
52-Week Range	5.83 - 12.60
Beta	n/a
Analysts	Strong Buy
Price Target	22.50 (+189.6%)
Earnings Date	Nov 8, 2021

About COGT

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and ...

IndustryBiotechnology

IPO DateMar 29, 2018

Employees15

Stock ExchangeNASDAQ

Ticker SymbolCOGT

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for COGT stock is "Strong Buy." The 12-month stock price forecast is 22.50, which is an increase of 189.58% from the latest price.

Price Target

$22.50

(189.58% upside)

Analyst Consensus: Strong Buy

Cogent Biosciences, Inc. (COGT)

About COGT

Financial Performance

Analyst Forecast

News

Cogent Biosciences Provides 2022 Corporate Guidance

Cogent Biosciences to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

Cogent Biosciences Provides Corporate Updates and Reports Third Quarter 2021 Financial Results

Cogent Biosciences to Present Virtually at Jefferies London Healthcare Conference 2021

Cogent Biosciences Presents New Preclinical Data Demonstrating Bezuclastinib as a Differentiated KIT Inhibitor with M...

Cogent Biosciences to Present Preclinical Data on Bezuclastinib at AACR-NCI-EORTC Conference

Cogent Biosciences Provides Corporate Updates and Reports Second Quarter 2021 Financial Results

Cogent Biosciences to Present at Wedbush PacGrow Virtual Healthcare Conference 2021

Cogent Biosciences to Present at Ladenburg Thalmann Virtual Healthcare Conference 2021

Cogent Biosciences to Present at Jefferies Virtual Healthcare Conference 2021

Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results

Cogent Biosciences Appoints Evan Kearns as Chief Legal Officer

Cogent Biosciences Announces Creation of Cogent Research Team

Cogent Biosciences, Inc. (COGT) Reports Q4 Loss, Lags Revenue Estimates

Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results

Cogent Biosciences Appoints Accomplished Finance Executive Todd E. Shegog to its Board of Directors

Cogent Biosciences to Present at Virtual 10th Annual SVB Leerlink Global Healthcare Conference 2021

Cogent Biosciences to Present at LifeSci Partners Virtual Precision Oncology Day 2021

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriter's Op...

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

Cogent Biosciences Announces $60.0 Million Public Offering of Shares of Common Stock

Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual Conference

Cogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare Conference

Cogent Biosciences Appoints Andrew Robbins as Chief Executive Officer

Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational P...